Advertisement
BDX vs SOLV
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Solventum Corporation (SOLV) Stock Comparison
Key Takeaways
- Becton, Dickinson and Company (BDX) has completed its transition into a focused medical technology company after spinning off its life sciences business, while Solventum Corporation (SOLV) remains in an active post-separation transformation following its 2024 spin-off from 3M.
- BDX is delivering broad-based, mid-single-digit revenue growth and has raised its full-year earnings outlook; SOLV is generating low-single-digit organic growth while rebuilding its commercial engine.
- Both companies face execution-related headwinds — BDX from tariffs and a recent regulatory warning letter, SOLV from elevated debt, separation costs, and ERP (enterprise resource planning) transitions.
- BDX offers a larger, more diversified revenue base and stronger free cash flow, while SOLV trades at a lower share price with a more turnaround-oriented risk profile.
- Market positioning favors BDX on consistency and stability, while SOLV presents a catalyst-driven story tied to cost savings and new product launches.
Introduction
Investors comparing healthcare stocks often weigh mature, diversified franchises against younger, restructuring-driven names. BDX and SOLV represent that contrast well. BDX, a century-old medical technology leader, has recently simplified itself into a pure-play device and delivery company. SOLV, spun off from 3M in 2024, is still working through its separation while building a standalone identity. This stock comparison examines relative performance, growth drivers, and market positioning to help both long-term investors and active traders assess which company currently offers the more compelling setup.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) is a global medical technology firm operating across four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. In February 2026, BD completed the spin-off of its Biosciences and Diagnostic Solutions business, leaving a more focused portfolio centered on drug delivery, patient monitoring, and procedural devices.
Recent market activity has reflected an improving execution story. In its most recent quarters, BD reported revenue above analyst expectations, with adjusted earnings per share (EPS) rising year over year, and it twice raised its full-year adjusted EPS outlook. Growth platforms such as biologic drug delivery, advanced patient monitoring, and wound care have posted double-digit gains. Sentiment has also been supported by a partnership with the U.S. government to expand domestic medical manufacturing. Offsetting factors include tariff-driven margin pressure and an FDA (U.S. Food and Drug Administration) warning letter tied to one manufacturing facility, which prompted a temporary U.S. shipment hold on certain infection-prevention products.
SOLV Overview and Recent Performance
Solventum Corporation (SOLV) is a healthcare company formed from 3M's former healthcare business, spanning three segments: MedSurg, Dental Solutions, and Health Information Systems. Since its 2024 spin-off, the company has been focused on commercial restructuring, portfolio optimization, and completing its technology separation from 3M.
Recent performance has shown gradual improvement beneath headline figures. In its latest quarter, SOLV beat adjusted EPS and organic sales expectations, with organic growth driven by advanced wound care, dental products, and revenue cycle management. Management affirmed and later raised full-year guidance, and the company is targeting roughly 20 new product launches over the next two years. However, reported net income remains pressured by separation and restructuring costs, and the balance sheet carries meaningful debt. Temporary benefits from advance orders ahead of ERP cutovers and tariff refunds have also created some quarterly noise, making underlying momentum a key area of investor focus.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates the platform's best-performing AI trading bots for current market conditions. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of securities. Rather than featuring every bot, this curated section highlights only those most suitable for today's environment, with many bots displaying metrics such as win rates, number of trades, and profitability statistics. Whether a trader favors short-term momentum or longer-horizon positioning, exploring these bots can provide an objective, algorithm-driven perspective on names like BDX and SOLV. Visit the Trending AI Robots page to review the current lineup.
Head-to-Head Comparison
The two companies differ most clearly in business model maturity and growth profile. BDX is a diversified, scaled operator with roughly $20 billion in annual revenue, high recurring consumables demand, and a disciplined capital-return program. Its recent spin-off has reduced complexity and concentrated the portfolio on faster-growing areas. SOLV is a smaller, roughly $8 billion-revenue business still absorbing separation costs and carrying net debt of about $4.7 billion, which limits near-term financial flexibility.
On momentum, BDX has demonstrated more consistent execution, with revenue, margins, and EPS generally ahead of expectations and a raised full-year outlook. SOLV's momentum is improving but choppier, influenced by order-timing effects and system transitions. From a risk standpoint, BDX faces tariff exposure and regulatory scrutiny, while SOLV faces integration risk, debt, and the execution burden of its multi-year transformation. Sector exposure also differs: BDX is concentrated in devices and drug delivery, whereas SOLV adds dental and healthcare software revenue streams. Ultimately, BDX offers stability and scale, while SOLV offers a catalyst-heavy turnaround narrative.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, free cash flow generation, and relative market positioning, Tickeron's AI would likely favor BDX in the current environment. Its broader diversification, consistent execution, and stronger cash flow profile suggest a more reliable near-term trend than a stock still working through separation-related volatility. SOLV is not without merit — improving organic growth, a $500 million cost-savings program, and a robust product pipeline could support catalysts over time. However, until those catalysts translate into steadier, less noisy results, the AI would probabilistically assign BDX the stronger risk-adjusted positioning of the two.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Hold and SOLV is a Hold.
BDX's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for BDX moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 19 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 57 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BDX just turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 27 of 48 cases over the following month. The odds of a continued upward trend are 56%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 133 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 111 of 219 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.128) is normal, around the industry mean (4.887). P/E Ratio (57.452) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.456). BDX has a moderately high Dividend Yield (0.022) as compared to the industry average of (0.006). P/S Ratio (2.290) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
SOLV's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for SOLV moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 14 of the 19 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 16 of 30 cases where SOLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOLV advanced for three days, in 99 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
SOLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SOLV as a result. In 22 of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
SOLV moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SOLV crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
The Aroon Indicator for SOLV entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 30 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SOLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.017) is normal, around the industry mean (4.887). P/E Ratio (10.334) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (1.220) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (1.871) is also within normal values, averaging (56.074).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BDX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 88 | |
SMR RATING 1..100 | 85 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 7 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BDX | SOLV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 55% | 2 days ago 49% |
| MACD ODDS (%) | 2 days ago 56% | N/A |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 52% | 2 days ago 64% |
| Advances ODDS (%) | 6 days ago 45% | 6 days ago 66% |
| Declines ODDS (%) | 2 days ago 42% | 2 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 56% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green while SOLV’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- SOLV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while SOLV’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- SOLV’s TA Score: 4 bullish, 5 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +3.43% price change this week, while SOLV (@Pharmaceuticals: Other) price change was +0.10% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.77%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +7.55%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
SOLV is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +1.60% | ||
| COO - BDX | 55% Loosely correlated | +1.65% | ||
| TMO - BDX | 50% Loosely correlated | +1.18% | ||
| BAX - BDX | 50% Loosely correlated | -1.92% | ||
| CNMD - BDX | 48% Loosely correlated | +3.32% | ||
| MMSI - BDX | 48% Loosely correlated | +1.36% | ||
More | ||||
SOLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, SOLV has been loosely correlated with ICUI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SOLV jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To SOLV | 1D Price Change % | ||
|---|---|---|---|---|
| SOLV | 100% | +1.58% | ||
| ICUI - SOLV | 49% Loosely correlated | -0.10% | ||
| BAX - SOLV | 48% Loosely correlated | -1.92% | ||
| ALGN - SOLV | 47% Loosely correlated | +1.00% | ||
| COO - SOLV | 45% Loosely correlated | +1.65% | ||
| BDX - SOLV | 45% Loosely correlated | +1.60% | ||
More | ||||